View as an RSS Feed
Final Frontiers Of The War On Cancer: PD-1 And T-Cells
- Cancer immunotherapy or “Immuno-oncology” has become a highly prioritized area of research and development for the pharmaceutical industry.
- The current data regarding the checkpoint inhibitors is quite remarkable when compared to historical drugs in the same disease indication.
- T cell- immunotherapies are new and represent a an emerging class of drugs that could take a significant steak in the cancer drug industry/market altogether.
- Focus On Cancer Immunotherapy Results
- Cancer Stem Cells: The Potential For Game Change In The Future Of Cancer Drug Development
- Discussion With Dr. George E. Peoples About NeuVax (E75) Cancer Vaccine
- Important Cancer Therapeutics Under Development To Watch II
- Important ASCO Updates On Immunotherapy Drug Treatments
- Important Cancer Therapeutics Under Development To Watch
- 2012 Meeting Of The American Society Of Clinical Oncology (ASCO) Part I
- Critical Success Factors For The Immunotherapy Race
- Cancer Vaccine Approaches: A Race For Dominance In The Field
- Overcoming The Challenges Of Cell-Based Cancer Immunotherapy
- Early Innovations In The Breast Cancer Therapeutic Market
- Cancer Stem Cell Therapeutics In Focus
- Current Trends In Cancer Therapeutic Development
- Society For Neuro-Oncology Annual Meeting: Excitement Builds Around Immunotherapy